Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surge
Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial and antifungal effects. In one embodiment, the solution is administered intraocularly after cataract surgery before insertion of a replacement intraocular lens, resulting in reduced posterior capsular opacification which may eliminate the need for a subsequent surgery. The solution may be one that is invasively administered, for example, an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be one that is non-invasively or topically administered in the form of drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease.
대표청구항▼
What is claimed is: 1. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigimentosa, or age related macular degeneration a composition in a
What is claimed is: 1. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigimentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition comprising a concentration ranging between 0.5%w/w to about 10%w/w of a macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic and/or mycophenolic acid in a diseased posterior segment ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 2. The method of claim 1 wherein the macrolide antibiotic is selected from the group consisting of tacrolimus, Cyclosporin A, sirolimus, ascomycin, and everolimus. 3. The method of claim 1 wherein the macrolide antibiotic is selected from the group consisting of erythromycin, azithromycin, clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, troleandomycin, roxithromycin, ABT-773, telithromycin, macrolides derived from leucomycins, and lincosamides. 4. The method of claim 1 wherein the composition is formulated as at least one selecting from the group consisting of a polymer, a microcapsule, a microsphere, a microvesicle, and a liposome. 5. The method of claim 1 for administration to at least one of an ocular mucosal surface or the conjunctiva. 6. The method of claim 1 wherein the concentration of the macrolide antibiotic and/or mycophenolic acid is from at least one of about 0.5%w/v to about 3%w/v, about 3%w/v to about 5%w/v, about 5%w/v, to about 10%w/v, or about 3%w/v to about 0.5%w/v. 7. The method of claim 1 for treating age related macular degeneration wherein the composition further comprises a cyclooxygenase inhibitor. 8. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigmentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition consisting essentially of tacrolimus at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 9. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigmentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition consisting essentially of Cyclosporin A at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 10. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigmentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition consisting essentially of sirolimus at a concentration from 0. 5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 11. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigmentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition consisting essentially of ascomycin at a concentration from 0. 5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 12. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule in a patient's eye comprising administering to the eye of a patient with retinopathy, retinitis pigmentosa, or age related macular degeneration a composition in an extended release formulation on a contact or intraocular lens, the composition consisting essentially of everolimus at a concentration from 0.5%w/v to about 10%w/v in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 13. A method to treat a posterior segment disease affecting at least one of a choroid, retina, uvea, or lens capsule of an eye in a patient having diabetic retinopathy, age related macular degeneration, or retinitis pigmentosa, the method comprising administering to the eye a composition comprising a concentration ranging between 0.1%w/w to about 10%w/w of a macrolide and/or mycophenolic acid in a pharmaceutically acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic and/or mycophenolic in a diseased posterior segment ocular structure sufficient to treat the affected choroid, retina, uvea, or lens capsule. 14. The method of claim 13 wherein the composition further comprises at least one cyclooxygenase inhibitor.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (40)
Yat Sun Or ; Tsvetelina Lazarova ; Sophie Binet ; Jianchao Wang, 14-membered macrolides derived from leucomycins.
Nelson, Kevin D.; Romero-Sanchez, Andres A.; Smith, George M.; Alikacem, Nadir; Radulescu, Delia; Waggoner, Paula; Hu, Zhibing, Drug releasing biodegradable fiber implant.
John W. Gibson ; Stacey A. Sullivan ; John C. Middleton ; Arthur J. Tipton, High viscosity liquid controlled delivery system and medical or surgical device.
Gregory, Susan A; Isakson, Peter C; Anderson, Gary, Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin.
Nussenblatt Robert B. (Bethesda MD) Palestine Alan G. (Potomac MD), Method of treating ocular diseases by periocular administration of cyclosporine A or G.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Heller Jorge (Woodside CA) Ng Steve Y. W. (San Francisco CA) Penhale Donald W. H. (Menlo Park CA), Polymers containing carboxy-ortho ester and ortho ester linkages.
Heller Jorge (Palo Alto CA) Helwing Robert F. (Sunnyvale CA) Penhale Donald W. (Cupertino CA), Polymers of di- (and higher functionality) ketene acetals and polyols.
Daniel Tuse ; Kristien Mortelmans ; Leslie A. Hokama ; Michael E. Selsted ; Larry L. Chapoy ; Michael H. Quinn, Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial.
Baker Robert K. ; Kayser Frank ; Bao Jianming ; Kotliar Andrew ; Parsons William H. ; Rupprecht Kathleen M., Triterpene derivatives with immunosuppressant activity.
McCaulley, James Allen; Oldfield, Terry Ann; Matosky, Andrew Joseph; Dobbs, Suzanne Winegar; Christian, Vicky Lynn, Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Kleinman, David M.; Nivaggioli, Thierry; Gerritsen, Mary E.; Weber, David A., Formulations and methods for vascular permeability-related diseases or conditions.
Dor, Philippe J. M.; Mudumba, Sreenivasu; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq; Takhar, Sudeep, Formulations for treating ocular diseases and conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Mudumba, Sreenivasu; Dor, Philippe J M; Nivaggioli, Thierry; Weber, David A.; Farooq, Sidiq, Liquid formulations for treatment of diseases or conditions.
Holzer, Frank; Gross, Dorothea, Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate and use of calcium chelating agent and ophthalmologically compatible viscosity regulator.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.